Executive Search and Leadership Development firm Borderless recently sponsored the Fourth Annual BioNJ CEO Summit, which brought together some of the most influential leaders in the life sciences industry to share their knowledge, experiences and views on today’s evolving market access and commercialization environment. Speakers explored issues and considerations that need to be addressed along the development continuum, including raising capital, pricing, post-launch and politics.
“A clear message was that biopharmaceutical companies must develop a strategy early for Market Access and begin implementation in the pre-clinical phase of drug development. A sharp focus on pricing and transparency – currently under public scrutiny in the US – reinforces our observation that the increased demand and competition for skilled Market Access professionals will not abate,” explains Borderless Consultant Andrei Costache.
BioNJ, The Gateway to Health, is a network of more than 400 Members, including Borderless, representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount.
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.